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Abstract
Background: A small region of about 70 kb on human chromosome 19q13.3 encompasses 4 genes of
which 3, ERCC1, ERCC2, and PPP1R13L (aka RAI) are related to DNA repair and cell survival, and one,
CD3EAP, aka ASE1, may be related to cell proliferation. The whole region seems related to the cellular
response to external damaging agents and markers in it are associated with risk of several cancers.
Methods: We downloaded the genotypes of all markers typed in the 19q13.3 region in the HapMap
populations of European, Asian and African descent and inferred haplotypes. We combined the European
HapMap individuals with a Danish breast cancer case-control data set and inferred the association between
HapMap haplotypes and disease risk.
Results: We found that the susceptibility haplotype in our European sample had increased from 2 to 50
percent very recently in the European population, and to almost the same extent in the Asian population.
The cause of this increase is unknown. The maximal proportion of overall genetic variation due to
differences between groups for Europeans versus Africans and Europeans versus Asians (the Fst value)
closely matched the putative location of the susceptibility variant as judged from haplotype-based
association mapping.
Conclusion: The combined observation that a common haplotype causing an increased risk of cancer in
Europeans and a high differentiation between human populations is highly unusual and suggests a causal
relationship with a recent increase in Europeans caused either by genetic drift overruling selection against
the susceptibility variant or a positive selection for the same haplotype. The data does not allow us to
distinguish between these two scenarios. The analysis suggests that the region is not involved in cancer
risk in Africans and that the susceptibility variants may be more finely mapped in Asian populations.
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A small region of about 70 kb on human chromosome
19q13.3 encompasses four genes of which three, ERCC1,
ERCC2, and PPP1R13L (aka RAI) are related to DNA
repair and cell survival, and one, CD3EAP, aka ASE1, may
be related to cell proliferation. Evidence suggests that the
genes are co-ordinately expressed [1] and the whole
region may be related to the cellular response to external
damaging agents [2] Figure 1 illustrates the region.
Studies of genetic epidemiology have implicated this
region as a risk determinant for multiple types of cancer in
Caucasians [3-8]. It may also be associated with cancer
risk among Chinese [9]. Extensive searches in the region
were carried out on the postmenopausal breast cancers of
the prospective study "Diet, Cancer and Health" using
nested, individually matched cases and controls. Each
group comprised 434 persons, imbedded in the 29 549
women of the population based cohort. We have so far
identified a polymorphism, called RAI-3'd1. The formal
designation of the polymorphism is
NT_011109.15g18147012dupATTTT(2_12). It is located
3' of the gene PPP1R13L and is the polymorphism with
the strongest association to postmenopausal breast cancer
among Danish women [10]. Recent data also point to a
functional difference of the RAI-3'd1 alleles: Studies using
electrophoretic mobility shift assays indicate that a typical
"long" alleles having 9 repeats binds nuclear proteins with
higher affinity than a typical "short" alleles (having 4
repeats). This suggests that the polymorphism has a role
in transcription (K.K. Nissen et al, manuscript in prepara-
tion). However, PPP1R13L and part of ERCC2 are located
in a haplotype-block with very limited recombination.
Moreover, not all polymorphisms in the region have been
tested, as some are located in regions of highly repetitive
DNA, so that design of relevant assays is very difficult.
Thus, a formal identification of the causative variation(s)
is still lacking and it is possible that some of the untested
polymorphisms are of significance. Certain other poly-
morphisms seem to play an additional role in specific can-
cers. For instance, a polymorphism in the 3' coding region
of ERCC2, called XPDe23 or K751Q, may interact with the
polymorphisms in or around PPP1R13L in determining
risk of lung cancer [8]. Finally, the region, in particular the
polymorphism ASE1e1 may also play a role in the prog-
nosis of certain cancers such as multiple myeloma [11]
and lung cancer (U. Vogel, et al, unpublished). Several
polymorphisms in the ERCC1 region have been associ-
ated with survival among cancer patients [12-14].
Helgason et al. [15] reported that a gene associated with
diabetes 2 susceptibility contained a variant haplotype
that appeared to have been selected for in Asian and Euro-
pean populations. Thus, disease susceptibility variants
may not always be selectively neutral even if they prima-
rily manifest themselves after reproductive age (see also
[16-19]). Indeed, the susceptibility variants in chromo-
some 19q13.3 appear to affect relatively young people
and can therefore have a selection against them both
directly through reproductive output and indirectly
through caring for children and grandchildren after men-
opause. If this is the case, they are only expected to reach
high frequency due to one of the following factors: 1) they
have a positive effect on some other trait, 2) they are
linked to a variant which is positively selected and thus
are pulled to high frequency by genetic hitch hiking, 3)
they have increased by genetic drift, e.g. during a popula-
tion bottleneck.
We therefore surveyed the 19q13.3 region for differences
in haplotype structure and frequencies in the HapMap
populations of European, Asian and African descent. We
found that the susceptibility haplotype has increased from
2 to 50 percent very recently in the European population,
and to almost the same extent in the Asian population.
The cause of this increase is unknown. The maximal Fst-
value closely matches the putative location of the suscep-
tibility variant as judged from haplotype-based associa-
tion mapping.
Methods
Ethical matters
This study was performed in compliance with the Helsinki
declaration. The project was approved by the Science Eth-
ical Committee of Copenhagen (j.nr: 01-345/93/(KF) 11-
037/01/11-124/01). Written and verbal informed consent
was obtained from all participants.
HapMap populations
The DNA samples come from a total of 270 people. The
Yoruba people of Ibadan, Nigeria, provided 30 trios (two
parents and an adult child). In Japan, 45 unrelated indi-
viduals from the Tokyo area provided samples. In China,
Cartoon of the region investigated in the current studyFigure 1
Cartoon of the region investigated in the current 
study. From [10].
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Thirty U.S. trios provided samples, which were collected
in 1980 from U.S. residents with northern and western
European ancestry by the Centre d'Etude du Polymor-
phisme Humain (CEPH). Data used was downloaded
from the genome variation server (GVS) at University of
Washington http://gvs-p.gs.washington.edu/GVS/. This
data was imported into Haploview 4.0 [20] where the
haplotype block structure of 23 common markers in CEU
was analysed in detail. Haplotype blocks in CEU were
defined using the criterion of Gabriel et al. [21]: a block is
created if 95% of informative (i.e. non-inconclusive)
comparisons are "strong LD", i.e. with D' > 0.7 for > 95%
of pairwise markers. The same blocks were manually
defined in the YRI and Asian populations for comparison.
All haplotypes with frequencies > 1% were displayed.
Typing strategy
We sequenced the region spanning from the 5' portion of
ERCC2 to the 3' portion of ERCC1 in 10 breast cancer
cases and 10 controls. The actual number of reliable
sequences varied somewhat from place to place. In total,
we discovered 106 polymorphisms including those that
were present in the NCBI's dbSNP. Of these 21 were found
to contain very little variation and for 14 we could not
develop a reliable assay due to repetitive sequences. Of the
remaining 71 SNPs, we report results from complete typ-
ing of 58 In addition to these SNP we typed 4 more out-
side the region to span the full 70 kb region. A full list of
the markers is available in the supplementary material
from [10].
Population differentiation (Fst)
We downloaded the chromosome 19 genotype data for
the populations from HapMap. For each shared SNP on
the chromosome we calculated the Fst statistic between the
CEU population and the YRI population (with 32,310
shared SNPs) and between the CEU population and the
pooled CHB and JPT populations (with 32,443 shared
SNPs).
To plot the distribution in Figure 2, we calculated the
empirical density function using the density function in R.
To obtain the 95% percentile we used the quantile func-
tion from R.
Imputation of genotypes using FastPHASE
We pooled the case/control individuals with GVS individ-
uals by considering the genotypes of markers that are not
in the case/control individuals as missing data. We then
imputed the most likely genotypes of the missing data
using FastPHASE, and this way increased the number of
markers in the case/control data from 58 SNPs to 125
SNPs. This allowed us to compare the inferred frequency
of the key 11-marker haplotype block in the Breast cancer
data set and test its association with disease as well as with
previously identified associated markers, e.g. RAI-3'd1.
Association mapping
We tested both typed and imputed SNPs for association
with breast cancer. We tested each marker individually
with a 3 × 2 χ2-test and tested haplotype-phenotype asso-
ciation using the Blossoc method [22].
For the single marker test we used the tool chisq_sma
available from[23] and for the Blossoc analysis we used
the Blossoc tool from [24] We ran chisq_sma with default
options and Blossoc with options "-m5-fH". Of the 125
SNPs we could not compute the single marker statistics in
29 cases, due to too few counts in at least one of the cells
of the contingency table. Figure 3A thus only shows 96
points, rather than 125. The Blossoc method can compute
scores for all 125 SNPs.
Results
In order to compare our case-control data to HapMap data
[25] we first downloaded all SNP data on 19q13.3 from
the European, Asian and Yoruban populations from the
Human Genome Variation Server http://gvs-p.gs.wash
ington.edu/GVS/. We combined the European data from
GVS with a Danish breast cancer case/control data set [10]
and used FastPHASE [26] to impute the SNPs not typed in
Distribution of Fst values on chromosome 19 between Europe-AfricaFigur  2
Distribution of Fst values on chromosome 19 
between Europe-Africa. Vertical line shows the 95% per-
centile and the red dots the observed Fst values in the candi-
date region.
0.0 0.2 0.4 0.6 0.8 1.0
0
2
4
6
8
Empirical differentiaton distribution
of CEU vs YRI on chromosome 19
Genomic position
F S
T
Empirical distribution
Markers in candidate region
95% quantilePage 3 of 8
(page number not for citation purposes)
BMC Medical Genetics 2009, 10:20 http://www.biomedcentral.com/1471-2350/10/20
Page 4 of 8
(page number not for citation purposes)
Association analysis on typed and imputed markersFigure 3
Association analysis on typed and imputed markers. A) Single marker association, B) Blossoc analysis. The blue dots 
indicate markers that were typed in the case/control data, while the red dots indicate markers that were imputed for the case/
control individuals using GVS data.
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BMC Medical Genetics 2009, 10:20 http://www.biomedcentral.com/1471-2350/10/20the case/control data but in the GVS data. Figure 3A shows
the individual p-values of association to disease for typed
SNPs (shown as blue dots) and imputed SNPs (shown as
red dots). The association is highest (P = 3.58 × 10-3) at
chromosome position 50,570,445, corresponding to the
marker RAI-3'7. Figure 3B shows a haplotype based anal-
ysis, called Blossoc [22] of the association of SNPs with
breast cancer. Blossoc uses hierarchical clustering of local
haplotypes to estimate the position of the putative causa-
tive variant. The maximum association was located at
50,570,814, closely corresponding to the marker RAI-
3'd3. With the imputed SNPs and haplotype analysis we
conclude, as in the previous study, that the maximal asso-
ciation of SNPs with breast cancer in this region was
located just 3' of PPP1R13L [10] and do not delimit the
position of the causative genetic variant further.
Next, we calculated Fst, the proportion of overall genetic
variation due to differences between groups for Europeans
versus Africans (Figure 4A) and Europeans versus Asians
(Figure 4B), using the HapMap SNPs. In the samples,
Europeans and Africans share 29 SNPs in the region and
Europeans and Asians share 30 SNPs in the region. A
genetic difference between Europeans and Africans was
distinctly present immediately 3' to the PPP1L13L and to
the left, while limited differences were present to the right,
with maximal values from chromosome position
50,568,000 to 50,575,000 (Figure 4A). A similar differ-
ence is not found when comparing Asia and Europe (see
Figure 4B), but we observed a similar tendency in the
comparison of Asians and Africans (not shown) albeit
with slightly lower values and possibly shifted slightly to
the left. Although we would generally consider an Fst-
value of 0.5 large, we still expect to find Fst > 0.5 in numer-
ous places in the genome. Figure 2 shows the empirical
distribution of Fst values between the HapMap European
and African populations across the entire chromosome
19. The 95% percentile, shown as a vertical line, was
0.4281. The Fst of the markers in the region are shown as
red dots. Of the 29 SNPs in the region, 13 are among the
5% most differentiated SNPs on the chromosome, but
there are many other SNPs with similarly high Fst values.
The relatively high differentiation combined with the
known association with cancer, however, prompted our
further investigation.
To elucidate further the ethnic differences in this region of
19q13.3 we calculated the frequencies of haplotypes in
the region for the three ethnic groups using the chimpan-
zee genome to identifying the ancestral form. The SNPs
used for this analysis are shown in Figure 5. Haplotypes
were phased by the default method in Haploview based
on pedigree information from the trio making up the data
sets for YRI and CEU. The haplotypes spanning the region
of maximal Fst could be broken down into several sub-
regions with considerable recombination in between. A
core region of 11 SNPs (from rs171140 to rs11878644 in
Figure 5) seemed rather well preserved. In this core region
one particular haplotype ACTCTGACTCC, which seemed
closest related to the chimpanzee haplotype, constituted
91 percent of the African chromosomes, but only 15 per-
cent of Europeans and 48 percent of the Asian. In contrast,
the haplotype CTCCATTTCGT was only present on 2 per-
cent of African chromosomes, but 50 percent European
and 43 percent Asian chromosomes. Thus, major shifts of
haplotype frequencies in this region seem to have taken
place in the evolution of the European and Asian popula-
tions. Remarkably, the haplotype CTCCATTTCGT, which
has increased in the European and Asian populations, is
in very strong LD with the prime candidate SNP for asso-
ciation with breast cancer, RAI-3'd1 (Figure 5d), in that all
chromosomes carrying the CTCCATTTCGT haplotype
also carries the risk allele at RAI-3'd1. Therefore, the CTC-
CATTTCGT haplotype is also an inferred risk allele by a
test of independence (P < 0.05).
Discussion
In this paper, we have held together two different sets of
DNA data, (1) a set of Danish women suffering from post-
menopausal breast cancer, and (2) the HapMap DNA data
from different ethnic groups. It appears that a haplotype
in a region of high association with breast cancer has pro-
liferated during the formation of the European popula-
tion and to a somewhat lesser extent in the formation of
the Asian population. In contrast, the most common
allele among Africans, which also seem to be the ancestral
form according to the Chimpanzee sequence, has dimin-
ished considerably in the "new" populations of Europe
and Asia. It is therefore likely that the susceptibility hap-
lotype is the derived state and that it increased in connec-
tion with the out-of-Africa expansion 60,000–100,000
years ago.
Remarkably, the accumulation of haplotypes runs contra
to what we would expect, if risk of breast cancer were a
selectable property. Specifically, the haplotype CTCCATT-
TCGT, which has accumulated about 30-fold in the tran-
sition from Africans to Europeans seems to be positively
associated with cancer risk.
It is possible that other phenotypes, also associated with
this haplotype, have exerted a stronger selective pressure
in the opposite direction during the development of the
derived populations, where adaptive evolution in
response to changing environment appears to have been
prominent but not yet disentangled [19,27,28]. Alterna-
tively, the accumulation of the cancer-prone haplotype
could be a result of genetic drift overriding weak selective
forces in the periods, when the derived non-African pop-
ulations were still quite small [16,29,30].Page 5 of 8
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The main haplotypes in the region for a) Europe), b) Asia and c) AfricaFigure 5
The main haplotypes in the region for a) Europe), b) Asia and c) Africa. The haplotypes blocks were defined applying 
the criterion of Gabriel et al. [21] on the CEU data. Haplotypes in different blocks are connected with thick lines if shared 
more than 10% and with thin lines if shared 1–10%. Numbers between blocks indicate average linkage disequilibrium measured 
as D' between adjacent blocks The ancestral state of each SNP was inferred from the chimpanzee sequence, using the genome 
variation server. The haplotype CTCCATTTCGT (block 3) has an increased frequency in CEU and consists mainly of derived 
alleles. It is an inferred risk variant in the Breast Cancer data set (panel d) and is in strong LD with previously identified suscep-
tibility markers (position of these shown above Figure, and frequency of Rai3'd1 is shown in panel d).
rs
7
4
9
1
5
 
 
rs
1
0
8
5
3
7
7
3
 
rs
1
7
9
9
7
8
7
 
rs
2
3
8
4
1
7
 
rs
2
3
8
4
1
6
 
rs
2
3
8
4
1
5
 
rs
1
7
1
1
4
0
 
rs
2
3
8
4
0
3
 
rs
2
3
8
4
0
4
 
rs
1
7
9
9
7
9
3
 
rs
2
3
8
4
0
5
 
rs
2
3
8
4
0
6
 
rs
2
3
8
4
0
7
 
rs
1
6
1
8
5
3
6
 
rs
1
7
9
9
7
8
3
 
rs
3
8
1
0
3
6
6
 
rs
1
1
8
7
8
6
4
4
 
rs
7
3
5
4
8
2
 
rs
2
3
3
6
2
1
9
 
rs
3
2
1
2
9
8
6
 
rs
3
2
1
2
9
6
5
 
rs
3
2
1
2
9
6
4
 
rs
3
2
1
2
9
6
1
 
CC        GCCG  
      
ACTCAGACTGT    
    
AGCCAA
 
 
Chimp
  allele
CEU
HCB/
JPT
YRI
rs numbers
Breast cancer cohort
     
   	 
   
   	 
   

   	 
  
?????????????????????????????????????
a.
b.
c.
d.
BMC Medical Genetics 2009, 10:20 http://www.biomedcentral.com/1471-2350/10/20Conclusion
We have analysed a region of 19q13.3 previously shown
to be associated with cancer. We find that the polymor-
phisms shared between the CEU and YRI HapMap popu-
lations are highly divergent: 13 out of 29 SNPs in the
region are in the 95% percentile of Fst statistics for the
chromosome.
A detailed analysis identified a haplotype found in low
frequency (2%) in Africans but in high frequency in Euro-
peans (49%) and Asians (43%). Based on a comparison
with the Chimpanzee genome, we conclude that this hap-
lotype is derived, and most likely has increased in fre-
quency in the European and Asian populations since the
out-of-Africa migration, rather than decreased in fre-
quency in the African population.
The haplotype is associated with increased risk of cancer,
including early postmenopausal breast cancer, and we
would a priori expect selection to work against it. The
increase in frequency in the European and Asian popula-
tions can be explained by either genetic drift or by selec-
tion for the haplotype. In the case of genetic drift, the
reduced effective population size during the out-of-Africa
migration could have lead to a reduction in selective pres-
sure against the haplotype, allowing it to increase in fre-
quency. Positive selection for the haplotype, in Europeans
and Asians but not in Africans, could be caused either by
the introduction of a new genetic variant on the haplotype
background, or by the changes in environment factors in
Europe and Asia. With the available data, we are not able
to distinguish between these scenarios.
Abbreviations
ASE1: Antisense ERCC1; CEU: CEPH Europeans from
Utah; ERCC1: Excision-Repair, Complementing Defec-
tive, In Chinese Hamster, 1; ERCC2: Excision-Repair,
Complementing Defective, In Chinese Hamster, 2; Fst:
proportion of overall genetic variation due to differences
between ethnic groups; PPP1R13L: Protein Phosphatase 1,
Regulatory Subunit 13-Like; RAI: RelA-Associated Inhibi-
tor; RAI-3'd1: NT_011109.15 g.18147012ATTTT(2_11)
coinciding with rs7255792; RAI-3'd3: rs3047560; RAI-
3'7: rs7252567; YRI: Yorubans from Ibadan, Nigeria.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
AT collected the DNAs. BAN, UV performed the genotyp-
ing. MHS and TM performed the analyses. LH, WY partic-
ipated in certain analyses. MHS, TM, BAN and LB planned
the investigations and discussed the results. MHS, TM and
BAN drafted the paper. All authors read and approved the
final manuscript.
Acknowledgements
MHS acknowledges funding from the EU funded PolyGene project.
TM acknowledges funding from the Danish Research Council (FNU grant 
272-07-0380).
BAN acknowledges funding from The NovoNordisk Foundation, The Lun-
dbeck Foundation, Fabrikant Einar Willumsens Mindelegat.
References
1. Vogel U, Nexo BA, Tjonneland A, Wallin H, Hertel O, Raaschou-
Nielsen O: ERCC1, XPD and RAI mRNA levels in lym-
phocytes are not associated with lung cancer risk in a pro-
spective study of Danes.  Mutation research 2006, 593(1–2):88-96.
2. Laska MJ, Strandbygard D, Kjeldgaard A, Mains M, Corydon TJ,
Memon AA, Sorensen BS, Vogel U, Jensen UB, Nexo BA: Expression
of the RAI gene is conducive to apoptosis: studies of induc-
tion and interference.  Experimental cell research 2007,
313(12):2611-2621.
3. Dybdahl M, Vogel U, Frentz G, Wallin H, Nexo BA: Polymorphisms
in the DNA repair gene XPD: correlations with risk and age
at onset of basal cell carcinoma.  Cancer Epidemiol Biomarkers Prev
1999, 8(1):77-81.
4. Nexo BA, Vogel U, Olsen A, Ketelsen T, Bukowy Z, Thomsen BL,
Wallin H, Overvad K, Tjonneland A: A specific haplotype of single
nucleotide polymorphisms on chromosome 19q13.2-3
encompassing the gene RAI is indicative of post-menopausal
breast cancer before age 55.  Carcinogenesis 2003, 24(5):899-904.
5. Rockenbauer E, Bendixen MH, Bukowy Z, Yin J, Jacobsen NR, Heda-
yati M, Vogel U, Grossman L, Bolund L, Nexo BA: Association of
chromosome 19q13.2-3 haplotypes with basal cell carci-
noma: tentative delineation of an involved region using data
for single nucleotide polymorphisms in two cohorts.  Carcino-
genesis 2002, 23(7):1149-1153.
6. Skjelbred CF, Saebo M, Nexo BA, Wallin H, Hansteen IL, Vogel U,
Kure EH: Effects of polymorphisms in ERCC1, ASE-1 and RAI
on the risk of colorectal carcinomas and adenomas: a case
control study.  BMC cancer 2006, 6:175.
7. Vogel U, Hedayati M, Dybdahl M, Grossman L, Nexo BA: Polymor-
phisms of the DNA repair gene XPD: correlations with risk
of basal cell carcinoma revisited.  Carcinogenesis 2001,
22(6):899-904.
8. Vogel U, Laros I, Jacobsen NR, Thomsen BL, Bak H, Olsen A, Bukowy
Z, Wallin H, Overvad K, Tjonneland A, et al.: Two regions in chro-
mosome 19q13.2-3 are associated with risk of lung cancer.
Mutation research 2004, 546(1–2):65-74.
9. Yin J, Vogel U, Ma Y, Qi R, Sun Z, Wang H: A haplotype encom-
passing the variant allele of DNA repair gene polymorphism
ERCC2/XPD Lys751Gln but not the variant allele of
Asp312Asn is associated with risk of lung cancer in a north-
eastern Chinese population.  Cancer genetics and cytogenetics 2007,
175(1):47-51.
10. Nexo BA, Vogel U, Olsen A, Nyegaard M, Bukowy Z, Rockenbauer
E, Zhang X, Koca C, Mains M, Hansen B, et al.: Linkage disequilib-
rium mapping of a breast cancer susceptibility locus near
RAI/PPP1R13L/iASPP.  BMC medical genetics 2008, 9:56.
11. Vangsted A, Gimsing P, Klausen TW, Nexo BA, Wallin H, Andersen
P, Hokland P, Lillevang ST, Vogel U: Polymorphisms in the genes
ERCC2, XRCC3 and CD3EAP influence treatment outcome
in multiple myeloma patients undergoing autologous bone
marrow transplantation.  Int J Cancer 2007, 120(5):1036-1045.
12. Moreno V, Gemignani F, Landi S, Gioia-Patricola L, Chabrier A, Blanco
I, Gonzalez S, Guino E, Capella G, Canzian F: Polymorphisms in
genes of nucleotide and base excision repair: risk and prog-
nosis of colorectal cancer.  Clin Cancer Res 2006, 12(7 Pt
1):2101-2108.
13. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V,
Taranchon E, Filipits M, Pirker R, Popper HH, et al.: DNA repair by
ERCC1 in non-small-cell lung cancer and cisplatin-based
adjuvant chemotherapy.  The New England journal of medicine
2006, 355(10):983-991.
14. Park DJ, Zhang W, Stoehlmacher J, Tsao-Wei D, Groshen S, Gil J, Yun
J, Sones E, Mallik N, Lenz HJ: ERCC1 gene polymorphism as a
predictor for clinical outcome in advanced colorectal cancerPage 7 of 8
(page number not for citation purposes)
BMC Medical Genetics 2009, 10:20 http://www.biomedcentral.com/1471-2350/10/20Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
patients treated with platinum-based chemotherapy.  Clin Adv
Hematol Oncol 2003, 1(3):162-166.
15. Helgason A, Palsson S, Thorleifsson G, Grant SFA, Emilsson V, Gun-
narsdottir S, Adeyemo A, Chen YX, Chen GJ, Reynisdottir I, et al.:
Refining the impact of TCF7L2 gene variants on type 2 dia-
betes and adaptive evolution.  Nature Genetics 2007,
39(2):218-225.
16. Blekhman R, Man O, Herrmann L, Boyko AR, Indap A, Kosiol C, Bus-
tamante CD, Teshima KM, Przeworskil M: Natural selection on
genes that underlie human disease susceptibility.  Current Biol-
ogy 2008, 18(12):883-889.
17. Gibson G: Human evolution: Thrifty genes and the dairy
queen.  Current Biology 2007, 17(8):R295-R296.
18. Novembre J, Pritchard JK, Coop G: Adaptive drool in the gene
pool.  Nature Genetics 2007, 39(10):1188-1190.
19. Sulem P, Gudbjartsson DF, Stacey SN, Helgason A, Rafnar T, Magnus-
son KP, Manolescu A, Karason A, Palsson A, Thorleifsson G, et al.:
Genetic determinants of hair, eye and skin pigmentation in
Europeans.  Nature Genetics 2007, 39(12):1443-1452.
20. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visu-
alization of LD and haplotype maps.  Bioinformatics (Oxford, Eng-
land) 2005, 21(2):263-265.
21. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B,
Higgins J, DeFelice M, Lochner A, Faggart M, et al.: The structure of
haplotype blocks in the human genome.  Science 2002,
296(5576):2225-2229.
22. Mailund T, Besenbacher S, Schierup MH: Whole genome associa-
tion mapping by incompatibilities and local perfect phyloge-
nies.  BMC Bioinformatics 2006, 7:454.
23. SMA   [http://www.birc.au.dk/~mailund/sma]
24. Blossoc   [http://www.birc.au.dk/~mailund/Blossoc]
25. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA,
Belmont JW, Boudreau A, Hardenbol P, Leal SM, et al.: A second
generation human haplotype map of over 3.1 million SNPs.
Nature 2007, 449(7164):851-U853.
26. Scheet P, Stephens M: A fast and flexible statistical model for
large-scale population genotype data: applications to infer-
ring missing genotypes and haplotypic phase.  Am J Hum Genet
2006, 78(4):629-644.
27. Balaresque PL, Ballereau SJ, Jobling MA: Challenges in human
genetic diversity: demographic history and adaptation.
Human Molecular Genetics 2007, 16:R134-R139.
28. Bustamante CD, Fledel-Alon A, Williamson S, Nielsen R, Hubisz MT,
Glanowski S, Tanenbaum DM, White TJ, Sninsky JJ, Hernandez RD, et
al.: Natural selection on protein-coding genes in the human
genome.  Nature 2005, 437(7062):1153-1157.
29. Kryukov GV, Pennacchio LA, Sunyaev SR: Most rare missense alle-
les are deleterious in humans: Implications for complex dis-
ease and association studies.  American Journal of Human Genetics
2007, 80(4):727-739.
30. McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioan-
nidis JPA, Hirschhorn JN: Genome-wide association studies for
complex traits: consensus, uncertainty and challenges.
Nature Reviews Genetics 2008, 9(5):356-369.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2350/10/20/pre
pubPage 8 of 8
(page number not for citation purposes)
